COMMUNIQUÉS West-GlobeNewswire

Sofwave to Participate in 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
27/07/2026
SAN CLEMENTE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
27/07/2026
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles [...]
Genvor’s Antimicrobial Peptides Advance into Sugar Beet Research
27/07/2026
Woodland, CA, July 27, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and [...]
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
27/07/2026
Board appointment adds proven medical device leadership MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive [...]
Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs
27/07/2026
Reintroduction reflects clinician input and Curium investments to support reliable, long-term U.S. supply BOSTON, July 27, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today the immediate reintroduction of Thallous [...]
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
27/07/2026
Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety [...]
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
27/07/2026
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna [...]
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
27/07/2026
— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — [...]
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
27/07/2026
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based [...]
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
27/07/2026
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific [...]
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
27/07/2026
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready third- [...]
Micron Biomedical Secures $4.5 Million Federal Contract to Develop First Dissolvable Microarray Radiation/Nuclear Medical Countermeasure
27/07/2026
Next generation approach strengthens national preparedness against nuclear threats by accelerating access to time-sensitive treatments that allow for longer shelf life, simplified distribution and self-administration [...]
Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
27/07/2026
LONG BEACH, Calif. and TORONTO, July 27, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (NYSE: GLAS) today announced that the Company has retained Matt Murphy, as [...]
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
27/07/2026
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet [...]
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
27/07/2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
27/07/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
27/07/2026
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Picard Medical Receives NYSE American Acceptance of Compliance Plan
27/07/2026
-Company continues advancing long-term growth strategy under accepted compliance plan- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), [...]
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
27/07/2026
VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the [...]

Pages